Literature DB >> 21502798

Complete biochemical control and pituitary adenoma disappearance in a child with gigantism: efficacy of octreotide therapy.

A Ciresi, M C Amato, A Galluzzo, C Giordano.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21502798     DOI: 10.1007/BF03347049

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


× No keyword cloud information.
  5 in total

1.  Long-acting peptidomimergic control of gigantism caused by pituitary acidophilic stem cell adenoma.

Authors:  H G Maheshwari; T R Prezant; V Herman-Bonert; H Shahinian; K Kovacs; S Melmed
Journal:  J Clin Endocrinol Metab       Date:  2000-09       Impact factor: 5.958

2.  Growth hormone-secreting pituitary adenomas in childhood and adolescence: features and results of transnasal surgery.

Authors:  T Abe; L A Tara; D K Lüdecke
Journal:  Neurosurgery       Date:  1999-07       Impact factor: 4.654

3.  Eight-year follow-up of a child with a GH/prolactin-secreting adenoma: efficacy of pegvisomant therapy.

Authors:  S Bergamaschi; C L Ronchi; C Giavoli; E Ferrante; E Verrua; D I Ferrari; A Lania; R Rusconi; A Spada; P Beck-Peccoz
Journal:  Horm Res Paediatr       Date:  2010-01-15       Impact factor: 2.852

4.  Five-year follow-up of a 13-year-old boy with a pituitary adenoma causing gigantism--effect of octreotide therapy.

Authors:  Ellen Schoof; Helmuth G Dörr; Wieland Kiess; Dieter K Lüdecke; Eduard Freitag; Volker Zindel; Wolfgang Rascher; Jörg Dötsch
Journal:  Horm Res       Date:  2004-01-23

5.  Treatment of pituitary gigantism with the growth hormone receptor antagonist pegvisomant.

Authors:  Naila Goldenberg; Michael S Racine; Pamela Thomas; Bernard Degnan; William Chandler; Ariel Barkan
Journal:  J Clin Endocrinol Metab       Date:  2008-05-20       Impact factor: 5.958

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.